Analyst Kyle Mikson CFA from Canaccord Genuity maintained a Hold rating on Repligen (RGEN – Research Report) and keeping the price target at $170.00.
Kyle Mikson CFA has given his Hold rating due to a combination of factors surrounding Repligen’s recent acquisition and its potential impact on the company’s financial performance. The purchase of 908 Devices’ bioprocessing process analytical technology assets is expected to enhance Repligen’s capabilities in both upstream and downstream bioprocessing. However, the acquisition is anticipated to be dilutive in 2025, with the company projecting it to become accretive by 2026.
Despite the potential for strong revenue growth in the Process Analytics franchise beyond 2025, the near-term financial impact and the transition period in 2025 contribute to the Hold rating. Mikson acknowledges the strategic benefits of the acquisition, including potential synergies in manufacturing and commercial operations, but remains cautious until Repligen demonstrates a return to stronger financial performance. This cautious stance reflects the need for Repligen to show sustainable financial improvement to justify a more favorable rating.
Mikson CFA covers the Healthcare sector, focusing on stocks such as Repligen, Natera, and Castle Biosciences. According to TipRanks, Mikson CFA has an average return of -16.8% and a 25.73% success rate on recommended stocks.
Questions or Comments about the article? Write to editor@tipranks.com